Home

Keith L Brownlie

CIK 1518575 · last filed 2026-06-29

Keith L Brownlie is a corporate insider who has filed 30 SEC Form 4 insider transactions across 7 companies since 2011. The most recent filing, for CLDX, was dated Jun 29, 2026.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

7

Total Filings

30

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
C/O CELLDEX THERAPEUTICS, INC
53 FRONTAGE ROAD, SUITE 220
HAMPTON, NJ 08827
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CLDX Director — $39.68 — $0 8 2026-06-29
Phio Pharmaceuticals Corp. (PHIOW) Delisted Director 20,000 $0.02 $464 $0 1 2019-02-15
SOLIGENIX, INC. (SNGXW) Delisted Director — $0.01 — $0 2 2018-09-28
Phio Pharmaceuticals Corp. (RXIIW) Delisted Director 10,000 — — $0 2 2018-08-03
Phio Pharmaceuticals Corp. (RXII) Delisted Director — — — $0 2 2016-02-12
Vyant Bio, Inc. (CGIX) Delisted Director — $4.61 — $0 1 2013-10-15
IMMUNE PHARMACEUTICALS INC (EPCT) Delisted Director — — — $0 2 2011-06-16

Recent Filings

30 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-29 CLDX Grant (A) — $0 EDGAR
2025-06-09 CLDX Grant (A) — $0 EDGAR
2024-06-17 CLDX Grant (A) — $0 EDGAR
2023-06-20 CLDX Grant (A) — $0 EDGAR
2022-06-17 CLDX Grant (A) — $0 EDGAR
2021-06-21 CLDX Grant (A) — $0 EDGAR
2020-06-19 CLDX Grant (A) — $0 EDGAR
2019-06-20 CLDX Grant (A) — $0 EDGAR
2019-02-15 Phio Pharmaceuticals Corp. (PHIOW) Delisted Grant (A) +10,000 $0 EDGAR
2018-09-28 SOLIGENIX, INC. (SNGXW) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 30
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.